Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alice T Shaw

Showing results (71-80 of 204) with videos related to

Pageof 21
Sort By:
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 12, 2018
Efficacy of Alectinib in Patients with ALK-Positive NSCLC and Symptomatic or Large CNS MetastasesJessica J Lin, Ginger Y Jiang, Nencyben Joshipura, et al.
Targeted Oncology|February 16, 2020
Brain Penetration of Lorlatinib: Cumulative Incidences of CNS and Non-CNS Progression with Lorlatinib in Patients with Previously Treated ALK-Positive Non-Small-Cell Lung CancerTodd M Bauer, Alice T Shaw, Melissa L Johnson, et al.
Proceedings of the National Academy of Sciences of the United States of America|April 20, 2011
Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALKRyohei Katayama, Tahsin M Khan, Cyril Benes, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|August 25, 2016
Acquired Resistance to First-Line Afatinib and the Challenges of Prearranged Progression BiopsiesMeghan Campo, David Gerber, Justin F Gainor, et al.
Lung Cancer (Amsterdam, Netherlands)|January 7, 2026
Real-world incidence, prevalence, and clinical impact of brain metastases in patients with ALK-positive metastatic non-small cell lung cancer treated with first-line ALK tyrosine kinase inhibitorsGeoffrey Liu, Devin Abrahami, Priya Ramachandran, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 13, 2022
Continuation of Lorlatinib in ALK-Positive NSCLC Beyond Progressive DiseaseSai-Hong I Ou, Benjamin J Solomon, Alice T Shaw, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 29, 2020
Clinicopathologic Characteristics of BRG1-Deficient NSCLCIbiayi Dagogo-Jack, Alexa B Schrock, Marina Kem, et al.
The Lancet. Oncology|December 4, 2012
Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 studyPasi A Jänne, Alice T Shaw, José Rodrigues Pereira, et al.
Neuro-Oncology|July 24, 2014
Significance of targeted therapy and genetic alterations in EGFR, ALK, or KRAS on survival in patients with non-small cell lung cancer treated with radiotherapy for brain metastasesKimberley S Mak, Justin F Gainor, Andrzej Niemierko, et al.
Experimental Hematology & Oncology|October 22, 2019
Identification of osimertinib-resistant <i>EGFR</i> L792 mutations by cfDNA sequencing: oncogenic activity assessment and prevalence in large cfDNA cohortStephen R Fairclough, Lesli A Kiedrowski, Jessica J Lin, et al.
Pageof 21

Showing results (71-80 of 204) with videos related to

Sort By:
Pageof 21
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 12, 2018
Efficacy of Alectinib in Patients with ALK-Positive NSCLC and Symptomatic or Large CNS MetastasesJessica J Lin, Ginger Y Jiang, Nencyben Joshipura, et al.
Targeted Oncology|February 16, 2020
Brain Penetration of Lorlatinib: Cumulative Incidences of CNS and Non-CNS Progression with Lorlatinib in Patients with Previously Treated ALK-Positive Non-Small-Cell Lung CancerTodd M Bauer, Alice T Shaw, Melissa L Johnson, et al.
Proceedings of the National Academy of Sciences of the United States of America|April 20, 2011
Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALKRyohei Katayama, Tahsin M Khan, Cyril Benes, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|August 25, 2016
Acquired Resistance to First-Line Afatinib and the Challenges of Prearranged Progression BiopsiesMeghan Campo, David Gerber, Justin F Gainor, et al.
Lung Cancer (Amsterdam, Netherlands)|January 7, 2026
Real-world incidence, prevalence, and clinical impact of brain metastases in patients with ALK-positive metastatic non-small cell lung cancer treated with first-line ALK tyrosine kinase inhibitorsGeoffrey Liu, Devin Abrahami, Priya Ramachandran, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 13, 2022
Continuation of Lorlatinib in ALK-Positive NSCLC Beyond Progressive DiseaseSai-Hong I Ou, Benjamin J Solomon, Alice T Shaw, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 29, 2020
Clinicopathologic Characteristics of BRG1-Deficient NSCLCIbiayi Dagogo-Jack, Alexa B Schrock, Marina Kem, et al.
The Lancet. Oncology|December 4, 2012
Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 studyPasi A Jänne, Alice T Shaw, José Rodrigues Pereira, et al.
Neuro-Oncology|July 24, 2014
Significance of targeted therapy and genetic alterations in EGFR, ALK, or KRAS on survival in patients with non-small cell lung cancer treated with radiotherapy for brain metastasesKimberley S Mak, Justin F Gainor, Andrzej Niemierko, et al.
Experimental Hematology & Oncology|October 22, 2019
Identification of osimertinib-resistant <i>EGFR</i> L792 mutations by cfDNA sequencing: oncogenic activity assessment and prevalence in large cfDNA cohortStephen R Fairclough, Lesli A Kiedrowski, Jessica J Lin, et al.
Pageof 21